Comparison Overview

Johnson & Johnson Innovative Medicine

VS

PT Kalbe Farma, Tbk

Johnson & Johnson Innovative Medicine

None
Last Update: 2025-12-01

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 17,292
Subsidiaries: 10
12-month incidents
0
Known data breaches
0
Attack type number
0

PT Kalbe Farma, Tbk

KALBE Building, Jl. Letjen Suprapto Kav 4, Jakarta, DKI Jakarta, ID, 10510
Last Update: 2025-12-01
Between 750 and 799

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,334
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Johnson & Johnson Innovative Medicine
100%
Compliance Rate
0/4 Standards Verified
PT Kalbe Farma, Tbk
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for PT Kalbe Farma, Tbk in 2025.

Incident History — Johnson & Johnson Innovative Medicine (X = Date, Y = Severity)

Johnson & Johnson Innovative Medicine cyber incidents detection timeline including parent company and subsidiaries

Incident History — PT Kalbe Farma, Tbk (X = Date, Y = Severity)

PT Kalbe Farma, Tbk cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
Incidents

No Incident

https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
Incidents

No Incident

FAQ

Johnson & Johnson Innovative Medicine company demonstrates a stronger AI Cybersecurity Score compared to PT Kalbe Farma, Tbk company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, PT Kalbe Farma, Tbk company has disclosed a higher number of cyber incidents compared to Johnson & Johnson Innovative Medicine company.

In the current year, PT Kalbe Farma, Tbk company and Johnson & Johnson Innovative Medicine company have not reported any cyber incidents.

Neither PT Kalbe Farma, Tbk company nor Johnson & Johnson Innovative Medicine company has reported experiencing a ransomware attack publicly.

Neither PT Kalbe Farma, Tbk company nor Johnson & Johnson Innovative Medicine company has reported experiencing a data breach publicly.

Neither PT Kalbe Farma, Tbk company nor Johnson & Johnson Innovative Medicine company has reported experiencing targeted cyberattacks publicly.

Neither Johnson & Johnson Innovative Medicine company nor PT Kalbe Farma, Tbk company has reported experiencing or disclosing vulnerabilities publicly.

Neither Johnson & Johnson Innovative Medicine nor PT Kalbe Farma, Tbk holds any compliance certifications.

Neither company holds any compliance certifications.

Johnson & Johnson Innovative Medicine company has more subsidiaries worldwide compared to PT Kalbe Farma, Tbk company.

Johnson & Johnson Innovative Medicine company employs more people globally than PT Kalbe Farma, Tbk company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Johnson & Johnson Innovative Medicine nor PT Kalbe Farma, Tbk holds SOC 2 Type 1 certification.

Neither Johnson & Johnson Innovative Medicine nor PT Kalbe Farma, Tbk holds SOC 2 Type 2 certification.

Neither Johnson & Johnson Innovative Medicine nor PT Kalbe Farma, Tbk holds ISO 27001 certification.

Neither Johnson & Johnson Innovative Medicine nor PT Kalbe Farma, Tbk holds PCI DSS certification.

Neither Johnson & Johnson Innovative Medicine nor PT Kalbe Farma, Tbk holds HIPAA certification.

Neither Johnson & Johnson Innovative Medicine nor PT Kalbe Farma, Tbk holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Sigstore Timestamp Authority is a service for issuing RFC 3161 timestamps. Prior to 2.0.3, Function api.ParseJSONRequest currently splits (via a call to strings.Split) an optionally-provided OID (which is untrusted data) on periods. Similarly, function api.getContentType splits the Content-Type header (which is also untrusted data) on an application string. As a result, in the face of a malicious request with either an excessively long OID in the payload containing many period characters or a malformed Content-Type header, a call to api.ParseJSONRequest or api.getContentType incurs allocations of O(n) bytes (where n stands for the length of the function's argument). This vulnerability is fixed in 2.0.3.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Description

Monkeytype is a minimalistic and customizable typing test. In 25.49.0 and earlier, there is improper handling of user input which allows an attacker to execute malicious javascript on anyone viewing a malicious quote submission. quote.text and quote.source are user input, and they're inserted straight into the DOM. If they contain HTML tags, they will be rendered (after some escaping using quotes and textarea tags).

Risk Information
cvss4
Base: 7.1
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

SysReptor is a fully customizable pentest reporting platform. Prior to 2025.102, there is a Stored Cross-Site Scripting (XSS) vulnerability allows authenticated users to execute malicious JavaScript in the context of other logged-in users by uploading malicious JavaScript files in the web UI. This vulnerability is fixed in 2025.102.

Risk Information
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N
Description

Taiko Alethia is an Ethereum-equivalent, permissionless, based rollup designed to scale Ethereum without compromising its fundamental properties. In 2.3.1 and earlier, TaikoInbox._verifyBatches (packages/protocol/contracts/layer1/based/TaikoInbox.sol:627-678) advanced the local tid to whatever transition matched the current blockHash before knowing whether that batch would actually be verified. When the loop later broke (e.g., cooldown window not yet passed or transition invalidated), the function still wrote that newer tid into batches[lastVerifiedBatchId].verifiedTransitionId after decrementing batchId. Result: the last verified batch could end up pointing at a transition index from the next batch (often zeroed), corrupting the verified chain pointer.

Risk Information
cvss4
Base: 8.0
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:U/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A flaw has been found in youlaitech youlai-mall 1.0.0/2.0.0. Affected is the function getById/updateAddress/deleteAddress of the file /mall-ums/app-api/v1/addresses/. Executing manipulation can lead to improper control of dynamically-identified variables. The attack can be executed remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 6.5
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
cvss3
Base: 6.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X